Pneumococcal vaccines GRADE assessments

GRADE assessment for pneumococcal vaccines

15-valent pneumococcal vaccine (Vaxnuevance, 15vPCV) in adults

Coversheet on evidence assessment by ATAGI using the GRADE framework for 15vPCV in adults

GRADE assessment for 15vPCV

• compared to 13-valent pneumococcal vaccine (13vPCV) in adults aged ≥70 years without specific risk factors
• compared to 13vPCV + 23-valent pneumococcal polysaccharide vaccine (23vPPV) in indigenous adults aged ≥50 years without specific risk factors
• compared to 13vPCV + 23vPPV in adults aged ≥18 years with specific risk factors

ATAGI recommendations

• Use of 15vPCV versus 13vPCV in adults aged ≥70 years without specific risk factors
• Use of 15vPCV+ 23vPPV versus 13vPCV + 23vPPV in indigenous adults aged ≥50 years without specific risk factors
• Use of 15vPCV + 23vPPV versus 13vPCV + 23vPPV in adults aged ≥18 years with specific risk factors

Note
These GRADE documents should be read as a supplement to the Australian Immunisation Handbook (Handbook) recommendations.

View the pneumococcal disease chapter in the Handbook here